Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025
Elutia reported Q3 2024 financial results, highlighting the first commercial implant of EluPro, their FDA-cleared antibiotic-eluting biologic envelope. Overall net sales decreased 3.3% to $5.9 million, with SimpliDerm sales growing 19% to $3.1 million. BioEnvelope products sales declined 12% to $2.3 million. The company reported net income of $1.3 million, primarily due to a $12.7 million non-cash warrant revaluation gain. EluPro has been submitted to over 100 hospital VACs, with 36 accounts actively ordering. The company maintains a strong cash position of $25.7 million and is preparing for EluPro's full commercial launch in January 2025.
Elutia ha riportato i risultati finanziari del terzo trimestre 2024, evidenziando il primo impianto commerciale di EluPro, il loro involucro biologico a rilascio di antibiotico approvato dalla FDA. Le vendite nette complessive sono diminuite del 3,3% a 5,9 milioni di dollari, con le vendite di SimpliDerm in crescita del 19% a 3,1 milioni di dollari. Le vendite dei prodotti BioEnvelope sono diminuite del 12% a 2,3 milioni di dollari. L'azienda ha riportato un reddito netto di 1,3 milioni di dollari, principalmente a causa di un guadagno di rivalutazione di warrant non monetari di 12,7 milioni di dollari. EluPro è stato presentato a oltre 100 VAC ospedalieri, con 36 conti che effettuano ordini attivi. L'azienda mantiene una solida posizione di liquidità di 25,7 milioni di dollari ed è in preparazione per il lancio commerciale completo di EluPro a gennaio 2025.
Elutia informó sobre los resultados financieros del tercer trimestre de 2024, destacando el primer implante comercial de EluPro, su sobre biológico liberador de antibióticos aprobado por la FDA. Las ventas netas totales disminuyeron un 3,3% a 5,9 millones de dólares, con ventas de SimpliDerm aumentando un 19% a 3,1 millones de dólares. Las ventas de productos BioEnvelope cayeron un 12% a 2,3 millones de dólares. La compañía reportó un ingreso neto de 1,3 millones de dólares, principalmente debido a una ganancia de revaluación de warrants no monetarios de 12,7 millones de dólares. EluPro ha sido presentado a más de 100 VAC hospitalarias, con 36 cuentas haciendo pedidos activos. La empresa mantiene una sólida posición de efectivo de 25,7 millones de dólares y se está preparando para el lanzamiento comercial completo de EluPro en enero de 2025.
엘루티아는 2024년 3분기 재무 결과를 발표하며 FDA 승인을 받은 항생제 방출 생물학적 봉투인 엘루프로의 첫 상업적 이식을 강조했습니다. 총 순매출은 3.3% 감소하여 590만 달러를 기록했으며, 심플리더름의 매출은 19% 증가하여 310만 달러에 달했습니다. BioEnvelope 제품의 매출은 12% 감소하여 230만 달러가 되었습니다. 회사는 비현금 우선주 재평가 이익으로 주로 1270만 달러의 순이익을 130만 달러로 보고했습니다. 엘루프로는 100개 이상의 병원 VAC에 제출되었으며, 36개의 계좌가 활발히 주문하고 있습니다. 회사는 2570만 달러의 강한 현금 보유고를 유지하고 있으며, 2025년 1월 엘루프로의 전체 상업적 출시에 대비하고 있습니다.
Elutia a annoncé les résultats financiers du troisième trimestre 2024, mettant en lumière le premier implant commercial de EluPro, leur enveloppe biologique libérant des antibiotiques et approuvée par la FDA. Les ventes nets totales ont diminué de 3,3 % pour atteindre 5,9 millions de dollars, tandis que les ventes de SimpliDerm ont augmenté de 19 % pour atteindre 3,1 millions de dollars. Les ventes des produits BioEnvelope ont chuté de 12 % pour atteindre 2,3 millions de dollars. L'entreprise a rapporté un revenu net de 1,3 million de dollars, principalement en raison d'un gain de réévaluation de bons non monétaires de 12,7 millions de dollars. EluPro a été soumis à plus de 100 VAC hospitalières, avec 36 comptes championnant des commandes actives. L'entreprise maintient une solide position de liquidités de 25,7 millions de dollars et se prépare au lancement commercial complet d'EluPro en janvier 2025.
Elutia hat die finanziellen Ergebnisse des dritten Quartals 2024 veröffentlicht und dabei das erste kommerzielle Implantat von EluPro, ihrem von der FDA zugelassenen antibiotikafreisetzenden biologischen Hüllenkonzept, hervorgehoben. Der Gesamtumsatz sank um 3,3 % auf 5,9 Millionen USD, während der Umsatz mit SimpliDerm um 19 % auf 3,1 Millionen USD stieg. Der Umsatz der BioEnvelope-Produkte fiel um 12 % auf 2,3 Millionen USD. Das Unternehmen berichtete von einem Nettogewinn von 1,3 Millionen USD, der hauptsächlich aufgrund eines nicht zahlungswirksamen Revaluationsgewinns bei Warrants in Höhe von 12,7 Millionen USD erzielt wurde. EluPro wurde bei über 100 Krankenhaus-VACs eingereicht, wobei 36 Konten aktiv Bestellungen aufgeben. Das Unternehmen hat eine starke Liquiditätsposition von 25,7 Millionen USD und bereitet sich auf die vollständige Markteinführung von EluPro im Januar 2025 vor.
- SimpliDerm sales increased 19% to $3.1 million
- Strong cash position of $25.7 million
- EluPro adoption reaching 25% of BioEnvelope sales
- 36 accounts actively ordering EluPro
- Net income of $1.3 million compared to previous loss of $8.5 million
- Overall net sales decreased 3.3% to $5.9 million
- BioEnvelope products sales declined 12% to $2.3 million
- Cardiovascular products sales decreased 40% to $0.6 million
- Operating expenses increased to $13.0 million from $10.2 million
- Adjusted EBITDA loss widened to $2.9 million from $1.7 million
Insights
The Q3 results present a mixed financial picture with concerning short-term trends but promising future catalysts. Overall revenue declined -3.3% to
The company's
EluPro's market entry shows promising early signals, capturing
The strategic focus on both cardiac and neurostimulation applications, coupled with advancing GPO discussions, positions EluPro for broader market penetration. The temporary CanGaroo sales decline reflects a natural transition as institutions await EluPro availability, rather than competitive losses.
Over 100 EluPro VAC Submissions and
SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024.
Business Highlights:
- First Commercial Use: Announced the first patient implant of EluPro, the FDA-cleared antibiotic-eluting biologic envelope for pacemakers and neurostimulators.
- Strong Initial Adoption: EluPro is being utilized across all major cardiac implantable electronic device (CIED) brands and in neurostimulation procedures. EluPro now accounts for
25% of BioEnvelope (CanGaroo and EluPro) sales. - Robust VAC Engagement: EluPro has now been submitted to over 100 hospital system value analysis committees (VACs), with 36 accounts now actively ordering.
- Expanded Sales Presence: Strengthened sales team in key markets including Southern California and the Northeast, balancing direct and independent representation for efficient, targeted coverage. Sales team now includes 12 direct reps, 34 independent reps, and 9 product consultants.
- GPO Access: Advanced discussions with major group purchasing organizations (GPOs), including private health systems and the Veterans Administration (VA), with favorable coverage decisions anticipated by early 2025 to expand EluPro’s national availability.
- Initiated Clinical Study: Started a multi-center registry study to evaluate outcomes of patients receiving EluPro during cardiac implantable electronic device (CIED) implantation.
- Peer Reviewed Publications: Data published in Frontiers in Drug Delivery journal showcasing EluPro’s effectiveness in eradicating bacteria linked to CIED infections, with additional manuscripts under review.
- Business Development Activity: Engaged in active discussions with multiple parties exploring opportunities for EluPro.
“We achieved several significant milestones this quarter, including the first implant of EluPro, marking a pivotal advancement for our team and the patients we serve,” said Dr. Randy Mills, Elutia’s Chief Executive Officer. “As we prepare for EluPro’s full commercial launch in January 2025, we are energized by the strong initial market interest and clinical adoption. With EluPro’s promising start and the continued momentum of SimpliDerm, we are redefining the BioEnvelope and reconstructive markets so that patients can thrive without compromise. I want to thank our unstoppable CRU for their exceptional efforts.”
Third Quarter 2024 Financial Results
For the three-month period ended September 30, 2024, as compared to the same period of 2023:
- Overall net sales decreased
3.3% to$5.9 million , compared to$6.1 million . - Net sales for BioEnvelope products, including both EluPro and CanGaroo, decreased by
12% , totaling$2.3 million compared to$2.6 million in Q3 2023, reflecting decreased sales of CanGaroo as customers anticipate the pending availability of EluPro in their accounts. - Net sales of SimpliDerm increased
19% to$3.1 million , compared to$2.6 million . - Net sales of Cardiovascular products were
$0.6 million , a decrease of40% , as LeMaitre Vascular continues transitioning Cardiovascular products into its sales strategy, in line with the Company’s exclusive distribution relationship. - Gross margin on a GAAP basis was
46% , approximately the same from the prior year period. - Adjusted gross margin (a non-GAAP measure which excludes non-cash amortization of intangibles) was
61% , compared to60% . A reconciliation of GAAP gross margin to adjusted gross margin is included in the accompanying financial tables. - Total operating expenses were
$13.0 million , compared to$10.2 million . The increase resulted primarily from higher non-cash equity compensation charges in the current year period. - Loss from operations was
$10.2 million , compared to$7.4 million . - Net income from continuing operations was
$1.3 million , compared to a loss of$8.5 million . The increase was primarily due to a$12.7 million non-cash gain in the third quarter of 2024 related to the revaluation of the Company’s liability on warrants and pre-funded warrants related to the Company’s 2023 and 2024 financings. - Adjusted EBITDA (a non-GAAP measure that excludes from net loss certain non-operating, non-cash and non-recurring items) was a loss of
$2.9 million , compared to a loss of$1.7 million . A reconciliation of net income (loss) to adjusted EBITDA is included in the accompanying financial tables. - Cash balance as of September 30, 2024, was
$25.7 million and includes approximately$13.8 million in proceeds received from the exercise of outstanding warrants at the start of the quarter.
Conference Call
Elutia will host a conference call today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss its third quarter 2024 financial results and performance.
The conference call can be accessed using the following information:
Webcast: Click here
U.S. Investors: 877-407-8029
International Investors: 201-689-8029
Conference ID: 13749386
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Non-GAAP Disclosure
In addition to the Company's financial results determined in accordance with U.S. GAAP, the Company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The Company presents in this press release the following non-GAAP financial measures: earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted earnings before interest, taxes, depreciation and amortization (“adjusted EBITDA”), adjusted gross margin and adjusted gross profit. The Company defines EBITDA as GAAP net loss excluding interest expense, income tax expense, depreciation and amortization, and the Company defines adjusted EBITDA as EBITDA excluding income from discontinued operations, stock-based compensation, FiberCel litigation costs, loss on extinguishment of debt, net of gain on debt forgiveness, loss or gain on revaluation of warrant liability and gain on revaluation of revenue interest obligation. The Company defines adjusted gross profit and adjusted gross margin as GAAP gross profit and GAAP gross margin, respectively, excluding amortization of acquired intangible assets. The amortization of these intangible assets will recur in future periods until such intangible assets have been fully amortized. Management believes that presentation of non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. The Company uses this non-GAAP financial information to establish budgets, manage the Company's business, and set incentive and compensation arrangements. Non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental information purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. For a reconciliation of these non-GAAP measures to GAAP, see below “Non-GAAP Reconciliations of EBITDA and Adjusted EBITDA” and “Non-GAAP Reconciliations of Adjusted Gross Profit and Adjusted Gross Margin.”
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including any statements and information concerning the launch of EluPro, including the timing and anticipated success thereof. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: our ability to successfully commercialize, marked and sell our newly approved EluPro product; our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits and claims; the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the November 2023 sale of our Orthobiologics business; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates; and our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2023, as such factors may be updated from time to time in Elutia’s other filings with the SEC, including Elutia’s Quarterly Reports on Form 10-Q, accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
| ELUTIA INC. | |||||||
| CONSOLIDATED BALANCE SHEET DATA | |||||||
| (Unaudited, in thousands) | |||||||
| Assets | September 30, 2024 | December 31, 2023 | |||||
| Current assets: | |||||||
| Cash | $ | 25,741 | $ | 19,276 | |||
| Accounts receivable, net | 2,931 | 3,263 | |||||
| Inventory | 3,633 | 3,853 | |||||
| Receivables of litigation costs | 4,582 | 2,696 | |||||
| Prepaid expense and other current assets | 431 | 2,165 | |||||
| Total current assets | 37,318 | 31,253 | |||||
| Property and equipment, net | 693 | 172 | |||||
| Intangible assets, net | 9,123 | 11,671 | |||||
| Operating lease right-of-use assets, and other | 1,273 | 332 | |||||
| Total assets | $ | 48,407 | $ | 43,428 | |||
| Liabilities and Stockholders' Deficit | |||||||
| Current liabilities: | |||||||
| Accounts payable and accrued expenses and other current liabilities | $ | 10,498 | $ | 12,676 | |||
| Current portion of long-term debt | - | 3,321 | |||||
| Current portion of revenue interest obligation | 4,400 | 11,741 | |||||
| Contingent liability for legal proceedings | 24,289 | 15,024 | |||||
| Current operating lease liabilities | 491 | 275 | |||||
| Total current liabilities | 39,678 | 43,037 | |||||
| Long-term debt | 22,641 | 20,356 | |||||
| Long-term revenue interest obligation | 6,244 | 5,360 | |||||
| Warrant liability | 18,527 | 12,760 | |||||
| Other long-term liabilities | 1,555 | 515 | |||||
| Total liabilities | 88,645 | 82,028 | |||||
| Stockholders' equity (deficit): | |||||||
| Common stock | 34 | 23 | |||||
| Additional paid-in capital | 180,260 | 137,021 | |||||
| Accumulated deficit | (220,532 | ) | (175,644 | ) | |||
| Total stockholders' deficit | (40,238 | ) | (38,600 | ) | |||
| Total liabilities and stockholders' deficit | $ | 48,407 | $ | 43,428 | |||
| ELUTIA INC. | |||||||||||||||
| CONSOLIDATED STATEMENT OF OPERATIONS | |||||||||||||||
| (Unaudited, in thousands, except share and per share data) | |||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net sales | $ | 5,922 | $ | 6,127 | $ | 18,907 | $ | 18,870 | |||||||
| Cost of goods sold | 3,181 | 3,286 | 10,524 | 9,943 | |||||||||||
| Gross profit | 2,741 | 2,841 | 8,383 | 8,927 | |||||||||||
| Operating expenses: | |||||||||||||||
| Sales and marketing | 2,989 | 2,802 | 9,628 | 10,514 | |||||||||||
| General and administrative | 4,521 | 2,757 | 14,266 | 10,137 | |||||||||||
| Research and development | 778 | 557 | 2,951 | 3,016 | |||||||||||
| FiberCel litigation costs | 4,683 | 4,096 | 8,757 | 7,278 | |||||||||||
| Total operating expenses | 12,971 | 10,212 | 35,602 | 30,945 | |||||||||||
| Loss from operations | (10,230 | ) | (7,371 | ) | (27,219 | ) | (22,018 | ) | |||||||
| Interest expense | 1,129 | 1,448 | 3,709 | 4,285 | |||||||||||
| Other (income) expense, net | (12,653 | ) | (312 | ) | 14,135 | (312 | ) | ||||||||
| Income (loss) before provision of income taxes | 1,294 | (8,507 | ) | (45,063 | ) | (25,991 | ) | ||||||||
| Income tax expense | 8 | 12 | 5 | 36 | |||||||||||
| Net income (loss) from continuing operations | 1,286 | (8,519 | ) | (45,068 | ) | (26,027 | ) | ||||||||
| Income (loss) from discontinued operations | - | (1,228 | ) | 180 | (2,315 | ) | |||||||||
| Net income (loss) | 1,286 | (9,747 | ) | (44,888 | ) | (28,342 | ) | ||||||||
| Net income (loss) attributable to common stockholders per share - basic | $ | 0.03 | $ | (0.57 | ) | $ | (1.65 | ) | $ | (1.72 | ) | ||||
| Net income (loss) attributable to common stockholders per share - diluted | $ | (0.33 | ) | $ | (0.57 | ) | $ | (1.65 | ) | $ | (1.72 | ) | |||
| Weighted average common shares outstanding - basic | 32,520,134 | 17,017,610 | 27,132,216 | 16,464,262 | |||||||||||
| Weighted average common shares outstanding - diluted | 35,520,938 | 17,017,610 | 27,132,216 | 16,464,262 | |||||||||||
| ELUTIA INC. | |||||||||||||||
| NON-GAAP RECONCILIATIONS OF ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN | |||||||||||||||
| (Unaudited, in thousands, except share and per share data) | |||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net sales | $ | 5,922 | $ | 6,127 | $ | 18,907 | $ | 18,870 | |||||||
| Gross profit | 2,741 | 2,841 | 8,383 | 8,927 | |||||||||||
| Intangible asset amortization expense | 849 | 849 | 2,547 | 2,547 | |||||||||||
| Adjusted gross profit (Non-GAAP) | $ | 3,590 | $ | 3,690 | $ | 10,930 | $ | 11,474 | |||||||
| Gross margin | 46.3 | % | 46.4 | % | 44.3 | % | 47.3 | % | |||||||
| Adjusted gross margin percentage (Non-GAAP) | 60.6 | % | 60.2 | % | 57.8 | % | 60.8 | % | |||||||
| ELUTIA INC. | |||||||||||||||
| NON-GAAP RECONCILIATIONS OF EBITDA AND ADJUSTED EBITDA | |||||||||||||||
| (Unaudited, in thousands, except share and per share data) | |||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net income (loss) | $ | 1,286 | $ | (9,747 | ) | $ | (44,888 | ) | $ | (28,342 | ) | ||||
| Interest expense(1) | 1,129 | 1,448 | 3,709 | 4,285 | |||||||||||
| Income tax expense | 8 | 12 | 5 | 36 | |||||||||||
| Depreciation and amortization | 862 | 942 | 2,588 | 2,854 | |||||||||||
| Earnings before interest, taxes, depreciation and amortization (“EBITDA”) (Non-GAAP) | 3,285 | (7,345 | ) | (38,586 | ) | (21,167 | ) | ||||||||
| Loss (income) from discontinued operations | - | 1,228 | (180 | ) | 2,315 | ||||||||||
| Stock-based compensation | 1,775 | 615 | 6,683 | 1,987 | |||||||||||
| FiberCel litigation costs(2) | 4,683 | 4,096 | 8,757 | 7,278 | |||||||||||
| (Gain) loss on revaluation of warrant liability(3) | (12,653 | ) | (1,070 | ) | 15,321 | (1,070 | ) | ||||||||
| Warrant issuance expenses | - | 758 | 257 | 758 | |||||||||||
| Gain on revaluation of revenue interest obligation(4) | - | - | (1,443 | ) | - | ||||||||||
| Adjusted EBITDA (Non-GAAP) | $ | (2,910 | ) | $ | (1,718 | ) | $ | (9,191 | ) | $ | (9,899 | ) | |||
| (1) | Represents interest expense recorded on all outstanding long-term debt as well as the revenue interest obligation. | |
| (2) | Represents FiberCel litigation costs consisting primarily of legal fees and the estimated and actual costs to resolve the outstanding FiberCel litigation cases offset by the estimated amounts recoverable and recovered under insurance, indemnity and contribution agreements for such costs. | |
| (3) | Represents non-cash expense attributable to the revaluation of Common Warrants and Prefunded Warrants issued in connection with a private offering of Class A common stock on September 21, 2023. | |
| (4) | Represents the gain on the revaluation of the revenue interest obligation. At each reporting period, the value of the revenue interest obligation is re-measured based on current estimates of future payments, with changes to be recorded in the consolidated statements of operations using the catch-up method. | |
FAQ
What was Elutia's (ELUT) revenue in Q3 2024?
How much did SimpliDerm sales grow for Elutia (ELUT) in Q3 2024?
What is the current cash position of Elutia (ELUT)?
When is EluPro's full commercial launch planned by Elutia (ELUT)?
